Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 07, 2026 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals Announces Publication of IMPROVE-DiCE Phase 2a Data in Circulation, Demonstrating Ninerafaxstat as a Potential First-in-Class Therapy Targeting Cardiac Energetics in Cardiometabolic Disease

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart failure with preserved ejection fraction (HFpEF) In...